OnKure Therapeutics, Inc. OKUR
2.90
(0.03)
(1.02%)
as of 25 Sep
- Market cap
- $118.7M
- P/E
- 0.0×
Follow OKUR
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 8.64 | 12.01 | 24.79 | 14.93 | 4.64 | 10.73 | 10.28 |
Net Debt/EBITDA |
— | 1.60 | 2.74 | 3.73 | 1.85 | 0.82 | 2.07 | 0.95 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 1.01 | 0.95 | 0.96 | 0.91 | 0.98 | 0.97 | 0.87 |
Capex/Depreciation |
— | 0.06 | (1.20) | (0.79) | 0.49 | (0.44) | (0.06) | (0.06) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 38.12% | 59.67% | (75.68%) | (42.04%) | 3,772.54% | (5,304.43%) | (74.39%) | |
| — | (97.52%) | (48.22%) | (38.01%) | (39.63%) | (49.07%) | (69.93%) | (67.24%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (55.16%) | (38.53%) | (26.92%) | (52.12%) | (126.50%) | (50.89%) | (107.17%) |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (64.26) | (91.52) | (21.04) | (19.48) | (122.59) | (14.84) | (3.84) |
Cash per Share |
— | 127.76 | 264.36 | 81.39 | 41.30 | 105.27 | 32.13 | 4.37 |
Shareholders Equity per Share |
— | 115.63 | 249.53 | 81.14 | 40.81 | 98.60 | 30.12 | 4.16 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 115.63 | 249.53 | 81.14 | 40.81 | 98.60 | 30.12 | 4.16 |
Free Cash Flow |
— | (12.52) | (18.56) | (38.18) | (47.71) | (34.79) | (51.17) | (51.87) |
Working Capital |
— | 22.47 | 50.45 | 147.53 | 99.23 | 26.48 | 102.47 | 54.92 |
Capital Expenditures |
— | (0.01) | (0.02) | (0.20) | (0.35) | (0.25) | (0.05) | (0.05) |
Net Current Asset Value |
— | 22.43 | 50.41 | 146.92 | 98.14 | 26.02 | 101.92 | 54.91 |
| Other line items | ||||||||
Quick Ratio |
— | 8.47 | 11.71 | 23.81 | 14.20 | 4.10 | 10.52 | 9.97 |
Depreciation/Fixed assets |
— | (1.46) | 0.29 | 1.19 | (1.57) | 0.39 | 0.78 | 1.34 |
Cash ROIC |
— | (26.55%) | (17.85%) | (12.95%) | (23.77%) | (62.18%) | (24.30%) | (45.51%) |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (64.22) | (91.40) | (20.94) | (19.33) | (121.73) | (14.83) | (3.83) |
Capex per Share |
— | (0.04) | (0.12) | (0.11) | (0.14) | (0.87) | (0.02) | 0.00 |
Average Payables |
— | 0.73 | 0.73 | 1.47 | 1.96 | 2.66 | 3.19 | 2.20 |
Average Assets |
— | 12.75 | 40.36 | 104.62 | 131.10 | 71.96 | 75.32 | 88.51 |
Average Common Equity |
— | (32.62) | (32.62) | 52.55 | 123.59 | (0.94) | 0.99 | 80.01 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates